Sundaram Acharya

About

I build next generation genome engineering systems using structural and functional approaches.I have co-developed India’s first engineered Cas9 platform (enFnCas9), protected by a granted US patent and licensed for therapeutic and diagnostic applications through commercial partners including the Serum Institute of India and CrisprBits. Currently, I am working on structural and functional analysis of a rare Type IV CRISPR system by employing cryo-EM, mechanistic molecular biochemistry, and AI-guided protein design to develop the next wave of programmable theranostic platforms.

Employment

Employment history is unavailable.

Education

• Institute of Genomics and Integrative Biology Doctor of Philosophy (PhD)
  2019 - 2023

Projects & Funding

Projects & funding information is unavailable.

Publications (4)

• PAM-flexible Engineered FnCas9 variants for robust and ultra-precise genome editing and diagnostics
  Nature Communications 2024 DOI: 10.1038/s41467-024-49233-w
  +Save
• Combination of engineered FnCas9 and extended gRNAs for PAM-flexible, robust and nucleobase specific editing and diagnostics
  2023 DOI: 10.21203/rs.3.rs-3104171/v1
  +Save
• Francisella novicida Cas9 interrogates genomic DNA with very high specificity and can be used for mammalian genome editing.
  Proceedings of the National Academy of Sciences of the United States of America 2019 DOI: 10.1073/pnas.1818461116
  +Save
• Over-expression of Hsp83 in grossly depleted hsrω lncRNA background causes synthetic lethality and l(2)gl phenocopy in Drosophila
  2018 DOI: 10.1101/420554
  +Save